REPL Replimune Group, Inc.

Sentiment & Price 1 ideas • 1 voices • 1 sources ▼
Sentiment Gauge
1
Bull
0
Bear
0
Watch
Bull 100% Bear 0%
Price & Sentiment
Loading chart...
Recent News Top Views ▼
No recent news for REPL
No theses available
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
News✓
Loading...
All directions✓
▲ Long✓
▼ Short✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
15:46
Apr 13
Philip Astley-Sparke Co-founder, Avanir Pharmaceuticals CNBC
Replimune's drug has strong efficacy and support.
The FDA rejection of Replimune's melanoma drug was unfair because the drug has strong efficacy data with a 34% remission rate and durable responses, it resensitizes patients to anti-PD-1 therapy, and has broad support from oncologists and patient advocacy groups, indicating that the drug should be approved and the company has promising prospects.
REPL
HIGH

About REPL Analyst Coverage

Buzzberg tracks REPL (Replimune Group, Inc.) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (100%). 1 total trade ideas tracked.